Actualités Algernon Pharmaceuticals Inc (QB) - AGNPF | Actions OTCMarkets

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on June 2, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND EXCHANGE...

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on May 9, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND EXCHANGE...

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on April 22, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on April 14, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on April 6, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...

Securities Registration (foreign Private Issuer) (f-1/a)

As filed with the U.S. Securities and Exchange Commission on March __, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...

Securities Registration (foreign Private Issuer) (f-1)

As filed with the U.S. Securities and Exchange Commission on February __, 2022 Registration No. [●] UNITED...

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW...

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for...

Small Company Offering and Sale of Securities Without Registration (d)

o NoneEntity Type0001642178Breathtec BioMedical, Inc.Breathtec Biomedical, Inc. x Corporation o Limited Partnership o Limited...

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory...

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency...

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Algernon Pharmaceuticals Inc (QB) (AGNPF)

Votre Hub pour des idées et discussions en direct en temps réel

AGNPF Actualités

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1)

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Small Company Offering and Sale of Securities Without Registration (d)

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Algernon Pharmaceuticals Inc (QB) (AGNPF) Actualités

Algernon Pharmaceuticals Inc (QB) (AGNPF)

Votre Hub pour des idées et discussions en direct en temps réel

AGNPF Actualités

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1/a)

Securities Registration (foreign Private Issuer) (f-1)

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Small Company Offering and Sale of Securities Without Registration (d)

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités